The Manila Times

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Event to be held January 6th, 2026, at 10 a.m. EST. BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ...

Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever ...
The Manila Times

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid ...
European Medical Journal

Trial Examines Azathioprine in Early Parkinson’s Disease

UK trial has found that azathioprine does not slow progression in early Parkinson’s disease, despite good tolerability. The ...
Wyoming Tribune Eagle

What's Happening, Dec. 18, 2025

THURSDAY ...